摘要:
The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity.
摘要:
New icosahedral borohydrates Cs2[closo-B12(OH)12]; Cs[closo-1-H-1-CB11(OH)11]; and closo-1,12-H2-1,12-C2B10(OH)10 are disclosed. Also set forth are their preparation by refluxing the icosahedral boranes [closo-B12H12]2−, [closo-1-CB11H12]− and closo-1,12-(CH2OH)2-1,12-C2B10H10 with a hydroxylating agent, preferably 30%w hydrogen peroxide.
摘要:
The present invention relates to a non-vesicular preparation comprising at least one cationic amphiphile in an aqueous environment, its production and use and a cationic liposome suspension obtainable thereof with increase drug trap ratio and its areas of application such as pharmacology and medicine, particularly its use as carrier system for active substances.
摘要:
The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity.
摘要:
New boron icosahedral ethers and esters formed from Cs2[closo-B12(OH)12],; Cs[closo-1-H-1-CB11(OH)11]; and closo-1,12-H2-1,12-C2B10(OH)10 are disclosed. Also set forth are their preparation by reacting the icosahedral boranes [closo-B12H12]2−, [closo-1-CB11H12]− and closo-1,12-(CH2OH)2-1,12-C2B10H10 with an acid anhdride or acid chloride to form the ester or an alkylating agent to form the ether.
摘要:
A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
摘要:
A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
摘要:
An improved method for producing a cationic liposomal preparation comprising a camptothecin drug with enhanced physical and chemical stability, a cationic liposomal preparation obtainable by this method and pharmaceutical compositions thereof are disclosed.
摘要:
A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
摘要:
A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.